Cost-savings or value capture: IVD industry at a crossroads
This article was originally published in Clinica
The in vitro diagnostic (IVD) industry is rooted in the hospital-based clinical lab. Historically, hospitals viewed their labs as cost centres rather than profit centres. Therefore, to sell more products to these clients, the IVD industry has focused on selling its customers greater efficiencies and cost savings. This has meant broader test panels on automated platforms which require less space and technical expertise to operate. This model has been quite successful for some time and, to date, the majority of IVD sales are still for relatively inexpensive routine chemistry and immunoassay test products performed in high volumes by hospital labs.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.